XNAS
ALZN
Market cap2mUSD
Jul 16, Last price
3.53USD
1D
11.36%
1Q
426.87%
IPO
-65.89%
Name
Alzamend Neuro Inc
Chart & Performance
Profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | 2016‑04 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 9,988 | 14,894 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,988) | (14,894) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (145) | ||||||||
Tax Rate | |||||||||
NOPAT | (9,988) | (14,749) | |||||||
Net income | (9,948) -33.14% | (14,878) 19.94% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,252 | 989 | |||||||
BB yield | -52.07% | -278.05% | |||||||
Debt | |||||||||
Debt current | 301 | ||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (75) | (5,141) | |||||||
Cash flow | |||||||||
Cash from operating activities | (8,270) | (8,923) | |||||||
CAPEX | (147) | ||||||||
Cash from investing activities | (147) | ||||||||
Cash from financing activities | 3,652 | 200 | |||||||
FCF | (7,615) | (14,726) | |||||||
Balance | |||||||||
Cash | 376 | 5,141 | |||||||
Long term investments | |||||||||
Excess cash | 376 | 5,141 | |||||||
Stockholders' equity | (54,020) | (44,063) | |||||||
Invested Capital | 51,727 | 47,108 | |||||||
ROIC | |||||||||
ROCE | 435.51% | ||||||||
EV | |||||||||
Common stock shares outstanding | 3,383 | 650 | |||||||
Price | 0.71 29.91% | 0.55 -46.34% | |||||||
Market cap | 2,405 575.97% | 356 -41.27% | |||||||
EV | 2,330 | 10,098 | |||||||
EBITDA | (9,938) | (14,870) | |||||||
EV/EBITDA | |||||||||
Interest | 10 | 8 | |||||||
Interest/NOPBT |